Direct acting antivirals – Safety updates
February 14, 2017 – The FDA announced class labeling revisions for all direct acting antivirals (DAAs) regarding the risk of hepatitis B virus reactivation in patients co-infected with hepatitis C virus (HCV) and hepatitis B virus (HBV).
Download PDF
